Day Traders, Penny Stocks, Stock Options, Futures and Forex

Bristol-Myers Squibb(BMY Quote) is buying biotech firm Medarex(MEDX Quote) for $2.1 billion to bolster the U.S. drugmaker's drug pipeline and capability to produce biologic drugs.
More on BMY
Overnight News on TheStreet.com: July 23Analyst's Toolkit: Bristol-Myers Measures UpMad About Options: Celgene FlashbackWall Street Confidential Podcast, July 8Cramer: Don't Forget About InnovationCramer: Defense Is Smokin'Obama-Proof: Pfizer, Bristol-Myers and Teva5 Dumbest Things on Wall Street: June 26Mad Money Post Game: Quest Vs. Lab Corp.Deal Reached to Cut Drug CostsMarket Activity
Medarex Inc.| MEDX UPThe deal, announced Wednesday night, values Medarex at $16 a share, a 90% premium to the company's $8.40 a share closing price. A $2.4 billion purchase price, which Bristol-Myers will pay in cash, is offset by $300 million on Medarex's books.
Medarex specializes in the production of protein-based drugs made in living cells engineered to produce human antibodies. These so-called biologic drugs are different from the chemical-based drugs typically developed and marketed by large pharmaceutical companies.
Bristol-Myers and Medarex already were partners on one such drug, ipilimumab, currently in a phase III study of skin cancer patients.
"Medarex's technology platform, people and pipeline provide a strong complement to our company's biologics strategy, specifically in immuno-oncology," said Bristol-Myers CEO James Cornelius, in a statement.
Medarex hasn't successfully developed any drugs on its own yet, but three drugs it helped manufacture for partners have been approved recently -- Johnson & Johnson's(JNJ Quote) Simponi and Stelara and Novartis'(NVS Quote) Ilaris. Medarex receives royalties on the sale of these products.
The company has seven drugs of its own in current clinical trials and another three under development by partners.
Bristol-Myers' decision to acquire Medarex, a biotech drug development partner, comes a little less than a year after Bristol-Myers was outbid to acquire another partner, the biotech firm ImClone Systems.
Eli Lilly(LLY Quote) purchased ImClone, developer of the cancer drug Erbitux, for $6.5 billion -- a bid that trumped Bristol-Myer's $4.7 billion bid.

Looking for hot information on market stocks? Subscribe now to the hottest newsletter with exceptional service to guide you!

pennyalerts.info

Finding High Revenue Growth Penny Stocks? Find no more, subscribe to our newsletter today!

__________________
Subscribe Now!